摘要
目的:探讨双相情感障碍(BD)躁狂发作患者采用齐拉西酮+碳酸锂治疗的效果及对血清肌酸激酶、肌酸激酶同工酶水平的影响。方法:选取赣州市第三人民医院2021年1—12月收治的BD躁狂发作患者126例,随机将其分为观察组和对照组,各63例。对照组患者接受碳酸锂治疗,观察组患者接受齐拉西酮+碳酸锂治疗。观察比较两组临床疗效和不良反应发生率,以及治疗前后杨氏躁狂状态评定量表(YMRS)、阳性和阴性精神症状评定量表(PANSS)、血清肌酸激酶及肌酸激酶同工酶水平。结果:与对照组相比,观察组总有效率明显更高(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);治疗后观察组YMRS评分、PANSS评分、血清肌酸激酶水平及肌酸激酶同工酶水平均显著低于对照组(P<0.05)。结论:齐拉西酮+碳酸锂治疗BD躁狂发作患者有较好效果,能有效改善临床症状,下调血清肌酸激酶及肌酸激酶同工酶水平,且安全性较高。
Objective:To explore the effect of Ziprasidone+Lithium Carbonate on patients with bipolar disorder(BD)manic episode and its influence on serum creatine kinase and creatine kinase isoenzyme levels.Method:A total of 126 patients with BD manic episode admitted to the Third People's Hospital of Ganzhou from January to December 2021 were randomly divided into observation group and control group,with 63 cases in each group.The control group received Lithium Carbonate treatment,and the observation group received Ziprasidone+Lithium Carbonate treatment.The clinical efficacy and incidence of adverse reactions,Young mania rating scale(YMRS),positive and negative syndrome scale(PANSS),the levels of serum creatine kinase and creatine kinase isoenzyme before and after treatment were observed and compared between the two groups.Result:Compared with the control group,the total effective rate of the observation group was significantly higher(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the scores of YMRS,PANSS,the levels of serum creatine kinase and creatine kinase isoenzymes in observation group were significantly lower than those in control group(P<0.05).Conclusion:Ziprasidone+Lithium Carbonate has a good effect in the treatment of patients with BD manic episode,which can effectively improve clinical symptoms,down-regulate serum creatine kinase and creatine kinase isoenzyme levels,and has a high safety.
作者
曾巾芬
邹蓉
刘小军
肖峰
ZENG Jinfen;ZOU Rong;LIU Xiaojun;XIAO Feng(Department of Psychiatry and Psychology,the Third People's Hospital of Ganzhou,Ganzhou 341000,China;不详)
出处
《中国医学创新》
CAS
2024年第17期128-131,共4页
Medical Innovation of China
关键词
齐拉西酮
碳酸锂
双相情感障碍
躁狂发作
Ziprasidone
Lithium
Carbonate
Bipolar disorder
Manic episode